Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Charles E. Geyer"'
Autor:
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Barry C Lembersky, Jong-Hyeon Jeong, Charles E Geyer, Louis Fehrenbacher, Stephen K Chia, Adam M Brufsky, Janice M Walshe, Gamini S Soori, Shaker R Dakhil, James L Wade, Edward C McCarron, Sandra M Swain, Norman Wolmark
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Background NSABP B-42 evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease-free after 5 years of aromatase inhibitor-based (AI) therapy. Seven-year results demonstrated a non-statistically significant t
Autor:
Maria D. Thomson, Charles E. Geyer, Richard F. Brown, Khalid Matin, Jordan M Alpert, Bonny B Morris
Publikováno v:
Translational Behavioral Medicine. 9:347-356
Patients’ ability to access their provider’s clinical notes (OpenNotes) has been well received and has led to greater transparency in health systems. However, the majority of this research has occurred in primary care, and little is known about h
Publikováno v:
The Oncologist. 23:481-488
Background Metaplastic breast cancer (MBC) is a rare disease subtype characterized by an aggressive clinical course. MBC is commonly triple negative (TN), although hormone receptor (HR) positive and human epidermal growth receptor 2 (HER2) positive c
Autor:
Debora Fumagalli, Ahwon Lee, Charles E. Geyer, Priya Rastogi, Edward H. Romond, Lynn C. Goldstein, Seung Il Kim, Joseph P. Costantino, Patrick G. Gavin, Megan L. Reilly, Chungyeul Kim, Noriko Tanaka, D. Lawrence Wickerham, Seong Rim Kim, Yusuke Taniyama, Louis Fehrenbacher, Eleftherios P. Mamounas, Olga L. Bohn, Sandra M. Swain, Soonmyung Paik, Hanna Bandos, Matthew Y. Remillard, Nicole L. Blackmon, Katherine L. Pogue-Geile, Nour Sneige, Norman Wolmark, Jong-Hyeon Jeong, Eike Burandt, Zachary D. Horne
Publikováno v:
JNCI: Journal of the National Cancer Institute. 105:1782-1788
National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab
Publikováno v:
Cameron, D, Casey, M, Oliva, C, Newstat, B, Imwalle, B & Geyer, C E 2010, ' Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer : final survival analysis of a phase III randomized trial ', Oncologist, vol. 15, no. 9, pp. 924-34 . https://doi.org/10.1634/theoncologist.2009-0181
The Oncologist
The Oncologist
The article presents final analyses of overall survival from a phase III trial of lapatinib and capecitabine in patients with human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer that progressed following p
Publikováno v:
JNCI: Journal of the National Cancer Institute. 100:2-4
In this issue of the Journal, Gennari et al. ( 1 ) report results of a meta-analysis of eight published studies that tested the worth of HER2 as a predictive marker of benefit from anthracycline regimens over nonanthracycline regimens. The test for t